Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  11:36 2022-09-30 am EDT
78.40 EUR   +0.72%
09/30Correction to Sanofi and Regeneron Pharmaceuticals Article on Sept. 28
DJ
09/30SocGen Board Said to Appoint Investment Banking Head as New Group CEO
MT
09/30SocGen picks investment banking boss Krupa as its next CEO
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SANOFI : UBS gives a Neutral rating

08/09/2022 | 01:29am EDT

UBS downgrades his rating from Buy to Neutral. The target price is decreased from EUR 118 to EUR 103.


© MarketScreener with dpa-AFX Analyser 2022
All news about SANOFI
09/30Correction to Sanofi and Regeneron Pharmaceuticals Article on Sept. 28
DJ
09/30SocGen Board Said to Appoint Investment Banking Head as New Group CEO
MT
09/30SocGen picks investment banking boss Krupa as its next CEO
RE
09/30SANOFI : Deutsche Bank sticks Neutral
MD
09/29Regeneron - dupixent approved by fda as the first and only treatment indicated for prur..
AQ
09/28Sanofi-Regeneron's Dupixent Wins First-in-Class US FDA Nod for Chronic Skin Disorder
MT
09/28Press Release : Dupixent® (dupilumab) approved by FDA as the first and only treatment indi..
GL
09/28Press Release : Dupixent® (dupilumab) approved by FDA as the first and only treatment indi..
GL
09/28Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Pru..
PR
09/28Regeneron Pharmaceuticals, Inc. and Sanofi Announce Approval of Dupixent® by FDA as the..
CI
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2022 42 406 M 41 582 M 41 582 M
Net income 2022 8 301 M 8 140 M 8 140 M
Net Debt 2022 7 803 M 7 652 M 7 652 M
P/E ratio 2022 11,9x
Yield 2022 4,56%
Capitalization 98 318 M 96 409 M 96 409 M
EV / Sales 2022 2,50x
EV / Sales 2023 2,29x
Nbr of Employees 95 442
Free-Float 87,9%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 78,40 €
Average target price 108,05 €
Spread / Average Target 37,8%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Director
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI-11.49%96 409
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY19.47%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296